Shufro Rose & Co. LLC Sells 477 Shares of Amgen Inc. (NASDAQ:AMGN)

Shufro Rose & Co. LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 1.1% in the fourth quarter, HoldingsChannel reports. The firm owned 42,259 shares of the medical research company’s stock after selling 477 shares during the period. Amgen makes up approximately 1.0% of Shufro Rose & Co. LLC’s holdings, making the stock its 29th largest holding. Shufro Rose & Co. LLC’s holdings in Amgen were worth $11,357,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. OFI Invest Asset Management bought a new stake in shares of Amgen during the 3rd quarter valued at $26,000. Briaud Financial Planning Inc bought a new stake in shares of Amgen during the 3rd quarter valued at $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen during the 4th quarter valued at $29,000. Providence Capital Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter valued at $30,000. Finally, Planned Solutions Inc. bought a new stake in shares of Amgen during the 4th quarter valued at $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $0.60 during mid-day trading on Friday, hitting $269.98. 2,436,959 shares of the company’s stock traded hands, compared to its average volume of 2,035,139. The company’s 50-day moving average is $275.10 and its two-hundred day moving average is $281.52. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market capitalization of $144.81 billion, a P/E ratio of 21.62, a PEG ratio of 2.61 and a beta of 0.58. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.09 EPS. On average, equities analysts anticipate that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMGN. Royal Bank of Canada restated an “outperform” rating and set a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. UBS Group lowered their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Oppenheimer restated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Finally, SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $296.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.